In patients with T2DM, SGLT-2 inhibitors work by decreasing the renal threshold for glucose (RTG), thus increasing the urinary excretion of glucose from the proximal tubule, providing a degree of glycemic control and decrease in systemic blood pressure [33]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.